EPHB2 and nasopharyngeal carcinoma: Predictive analyses revealed several putative targets with the potential to interact with tRF-1:28-Val-CAC-2, EPHB2 is one of the potential targets, and high expression of EPHB2 predicts poor clinical outcomes in NPC patients.